Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Mallinckrodt
Chinese Patent Office
McKesson
Healthtrust
AstraZeneca
Express Scripts
Cantor Fitzgerald
Argus Health
Citi

Generated: October 17, 2017

DrugPatentWatch Database Preview

TAGAMET Drug Profile

« Back to Dashboard

Which patents cover Tagamet, and when can generic versions of Tagamet launch?

Tagamet is a drug marketed by Glaxosmithkline and Medtech Products and is included in six NDAs.

The generic ingredient in TAGAMET is cimetidine hydrochloride. There are twenty-five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the cimetidine hydrochloride profile page.

Summary for Tradename: TAGAMET

US Patents:0
Applicants:2
NDAs:6
Bulk Api Vendors: see list91
Clinical Trials: see list3
Patent Applications: see list671
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TAGAMET at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline
TAGAMET
cimetidine
TABLET;ORAL017920-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Medtech Products
TAGAMET HB
cimetidine
TABLET;ORAL020238-001Jun 19, 1995DISCNYesNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline
TAGAMET
cimetidine
TABLET;ORAL017920-005Apr 30, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
Medtech Products
TAGAMET HB
cimetidine
TABLET;ORAL020238-002Aug 21, 1996OTCYesYes► Subscribe► Subscribe► Subscribe
Glaxosmithkline
TAGAMET
cimetidine
TABLET;ORAL017920-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline
TAGAMET
cimetidine
TABLET;ORAL017920-004Dec 14, 1983DISCNNoNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline
TAGAMET
cimetidine hydrochloride
INJECTABLE;INJECTION017939-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline
TAGAMET
cimetidine hydrochloride
SOLUTION;ORAL017924-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
cimetidine hydrochloride
INJECTABLE;INJECTION019434-001Oct 31, 1985DISCNYesNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline
TAGAMET HB 200
cimetidine
SUSPENSION;ORAL020951-001Jul 9, 1999DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TAGAMET

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline
TAGAMET
cimetidine
TABLET;ORAL017920-004Dec 14, 1983► Subscribe► Subscribe
Glaxosmithkline
TAGAMET
cimetidine
TABLET;ORAL017920-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Glaxosmithkline
TAGAMET
cimetidine
TABLET;ORAL017920-005Apr 30, 1986► Subscribe► Subscribe
Glaxosmithkline
TAGAMET
cimetidine hydrochloride
SOLUTION;ORAL017924-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Glaxosmithkline
TAGAMET
cimetidine
TABLET;ORAL017920-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Glaxosmithkline
TAGAMET
cimetidine hydrochloride
INJECTABLE;INJECTION017939-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Glaxosmithkline
TAGAMET
cimetidine
TABLET;ORAL017920-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Glaxosmithkline
TAGAMET
cimetidine
TABLET;ORAL017920-004Dec 14, 1983► Subscribe► Subscribe
Glaxosmithkline
TAGAMET
cimetidine
TABLET;ORAL017920-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Glaxosmithkline
TAGAMET
cimetidine
TABLET;ORAL017920-005Apr 30, 1986► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Dow
Moodys
Cerilliant
Harvard Business School
Healthtrust
Deloitte
Covington
Chinese Patent Office
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot